Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College), Hangzhou, Zhejiang Province, 310014, China.
Department of Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310000, China.
Biomed Pharmacother. 2018 Jul;103:645-652. doi: 10.1016/j.biopha.2018.04.037. Epub 2018 Apr 24.
Our previous study has reported that BCL6 corepressor like 1 (BCORL1) plays an oncogenic role in hepatocellular carcinoma (HCC) via promoting epithelial-mesenchymal transition (EMT) and tumor metastasis. However, the regulation of BCORL1 mediated by microRNAs (miRNAs) remains poorly known. The analysis of our clinical samples indicated that BCORL1 expression was markedly higher in HCC tissues than that in tumor-adjacent normal tissues. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets revealed that high BCORL1 expression associated with high tumor grade, advanced tumor stage and poor survival of HCC patients. miR-875-5p expression was down-regulated and negatively correlated with BCORL1 mRNA expression in HCC tissues. Furthermore, miR-876-5p inversely regulated BCORL1 abundance in HCC cells by directly targeting the 3'-untranslated region (3'-UTR) of BCORL1. Ectopic expression of miR-876-5p suppressed cell migration and invasion in both HCCLM3 and MHCC97H cells. In accordance, miR-876-5p knockdown promoted the metastatic behaviors of Hep3B cells. Mechanistically, miR-876-5p suppressed the EMT progression of HCC cells. HCC tissues with high miR-876-5p level showed a higher E-cadherin staining compared to cases with low miR-876-5p level. Moreover, the repression of cell metastasis mediated by miR-876-5p was rescued by BCORL1 restoration in HCCLM3 cells. Notably, low miR-876-5p expression associated with venous infiltration, high tumor grade and advanced tumor stage. HCC patients with low miR-876-5p expression had a significant poorer overall survival and disease-free survival. To conclude, miR-876-5p inhibits EMT progression, migration and invasion of HCC cells by targeting BCORL1. Therefore, miR-876-5p/BCORL1 axis may represent as a novel therapeutic target for HCC treatment.
我们之前的研究表明,BCL6 核心抑制因子样 1(BCORL1)通过促进上皮间质转化(EMT)和肿瘤转移在肝细胞癌(HCC)中发挥致癌作用。然而,miRNAs(miRNAs)对 BCORL1 的调节仍知之甚少。对我们临床样本的分析表明,BCORL1 在 HCC 组织中的表达明显高于肿瘤相邻正常组织。癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)数据集显示,BCORL1 高表达与 HCC 患者的高肿瘤分级、晚期肿瘤分期和不良预后相关。miR-875-5p 在 HCC 组织中的表达下调,并与 BCORL1 mRNA 表达呈负相关。此外,miR-876-5p 通过直接靶向 BCORL1 的 3'-非翻译区(3'-UTR),反向调节 HCC 细胞中 BCORL1 的丰度。外源性表达 miR-876-5p 抑制 HCCLM3 和 MHCC97H 细胞的迁移和侵袭。相应地,miR-876-5p 敲低促进 Hep3B 细胞的转移行为。在机制上,miR-876-5p 抑制 HCC 细胞的 EMT 进展。与 miR-876-5p 水平低的 HCC 组织相比,miR-876-5p 水平高的 HCC 组织中 E-钙黏蛋白染色更高。此外,在 HCCLM3 细胞中,BCORL1 的恢复挽救了由 miR-876-5p 介导的细胞转移抑制作用。值得注意的是,低 miR-876-5p 表达与静脉浸润、高肿瘤分级和晚期肿瘤分期相关。miR-876-5p 表达低的 HCC 患者总生存率和无病生存率显著降低。总之,miR-876-5p 通过靶向 BCORL1 抑制 HCC 细胞的 EMT 进展、迁移和侵袭。因此,miR-876-5p/BCORL1 轴可能成为 HCC 治疗的新治疗靶点。